Mana.bio, a seed-stage biotech company pioneering the use of  artificial intelligence (AI) and machine learning ...

ESO-T01 is the first in vivo BCMA CAR-T candidate to reach the clinical stage MONT-SAINT-GUIBERT, Belgium, Dec. 11, 2024 (GLOBE NEWSWIRE) -- EsoBiotec SA, a biotechnology company empowering cells in ...

An emerging class of anticancer drugs called EZH2 inhibitors may greatly enhance the potency of some cancer immunotherapies, according to a ...

This research report provides valuable insights into the current market situation, drawing information and analysis from various sources. It scrutinizes prominent industry players, presenting details ...

Researchers at Northwestern University and the Uniformed Services University (USU) have decoded the mechanism behind the ...

An emerging class of anticancer drugs called EZH2 inhibitors may greatly enhance the potency of some cancer immunotherapies.

The non-cryopreserved CD19- and CD20-directed CAR T-cell therapy zamto-cel is manufactured in a closed-system device that ...

CRISPR Therapeutics (CRSP) presented data from the Company’s ongoing Phase 1/2 dose escalation clinical trial evaluating the safety and ...

In particular, patients who had fewer than 10 annual vaso-occlusive events before the gene therapy were more likely to have ...

The PCSK9 protein binds to LDL receptors (LDLR), leading to their degradation and reduced expression on cell surfaces. This decreased the clearance of LDL cholesterol from the bloodstream, thereby ...

A study in mice offers evidence that inhibiting EZH2 can enhance lymphoma immunogenicity and overcome CAR-T cell therapy resistance.